v3.26.1
Intangible Assets (Tables)
 12 Months Ended
Mar. 31, 2026
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Schedule of Reconciliation of the Activity Affecting Intangible Assets
A reconciliation of the activity affecting intangible assets, net for each of 2026 and 2025 is as follows:
Year Ended March 31, 2026
(In thousands)Indefinite-
Lived
Tradenames		Finite-Lived
Tradenames and Customer Relationships		Totals
Gross Carrying Amounts   
Balance – March 31, 2025$2,136,986 $434,500 $2,571,486 
Additions (a)
— 13,865 13,865 
Effects of foreign currency exchange rates6,689 1,765 8,454 
Balance – March 31, 2026$2,143,675 $450,130 $2,593,805 
Accumulated Amortization   
Balance – March 31, 2025$— $276,136 $276,136 
Additions— 17,919 17,919 
Effects of foreign currency exchange rates— 145 145 
Balance – March 31, 2026$— $294,200 $294,200 
Intangible assets, net – March 31, 2026$2,143,675 $155,930 $2,299,605 
Intangible Assets, net by Reportable Segment:
North American OTC Healthcare$2,068,752 $138,903 $2,207,655 
International OTC Healthcare74,923 17,027 91,950 
Intangible assets, net – March 31, 2026$2,143,675 $155,930 $2,299,605 
(a)On October 31, 2025, we completed the acquisition of Feminax. In connection with this asset acquisition, we allocated the entire purchase price of $13.9 million to intangible assets.
Year Ended March 31, 2025
(In thousands)Indefinite-
Lived
Tradenames		Finite-Lived
Tradenames and Customer Relationships		Totals
Gross Carrying Amounts   
Balance – March 31, 2024$2,167,162 $411,258 $2,578,420 
Additions (a)
6,850 1,400 8,250 
Reclassifications (b)
(28,982)28,982 — 
Tradename impairment(6,552)(5,914)(12,466)
Effects of foreign currency exchange rates(1,492)(1,226)(2,718)
Balance – March 31, 2025$2,136,986 $434,500 $2,571,486 
Accumulated Amortization   
Balance – March 31, 2024$— $257,837 $257,837 
Additions— 18,263 18,263 
Effects of foreign currency exchange rates— 36 36 
Balance – March 31, 2025$— $276,136 $276,136 
Intangible assets, net – March 31, 2025$2,136,986 $158,364 $2,295,350 
Intangible Assets, net by Reportable Segment:
North American OTC Healthcare$2,068,752 $141,234 $2,209,986 
International OTC Healthcare68,234 17,130 85,364 
Intangible assets, net – March 31, 2025$2,136,986 $158,364 $2,295,350 
(a) Amounts relate to our acquisition of Hydralyte intellectual property on October 1, 2024, giving us the rights to the Hydralyte intellectual property in all remaining jurisdictions with the exception of the United States.
(b) In connection with our annual impairment test at February 28, 2025, certain indefinite-lived intangible assets were moved to finite-lived to better reflect our long-term projections for these brands.
Schedule of Expected Amortization Expense At March 31, 2026, finite-lived intangible assets are expected to be amortized over their estimated useful lives, which range from a period of 10 to 24 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):
(In thousands)
Year Ending March 31,Amount
2027$16,481 
202814,157 
202914,144 
203014,005 
203113,975 
Thereafter83,168 
 $155,930